Cns Pharmaceuticals, Inc. · NASDAQ:CNSP
Cns Pharmaceuticals — Investor Presentation (March 2026)
12 slides from Cns Pharmaceuticals's investor presentation, March 2026
Slide 1: Investor Presentation
cnspharma.com NASDAQ: CNSP March 2026 Investor Presentation
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation incorporates information from materials filed with the SEC and contains forward-looking statements. All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial pos
Slide 3: Launch of New Corporate Growth Strategy Led By New Executive Team
Launch of New Corporate Growth Strategy Led By New Executive Team With a newly installed, highly experienced executive team, we are executing a decisive strategic pivot to reposition the company for long-term success. By combining disciplined capital allocation, data-driven decision making and focus
Slide 4: Investment Highlights
Investment Highlights Formal asset search underway targeting high- value preclinical / clinical-stage programs Purpose-Built Executive Team Highly experienced executive team with deep expertise in Targeting assets with strong biological rationale, neurology, oncology and rare disease drug develo
Slide 5: Rapid Execution with Key Building Blocks in Place
Rapid Execution with Key Building Blocks in Place CNS’s New Focus January March Asset Evaluation Asset Acquisition Asset Development Rami Levin Accomplished executive team with specific & appointed CEO CFO, CTO, CMO relevant experience & CBO appointed a Strategic pivot to be built around innovative
Slide 6: Purpose-Built Executive Team
Purpose-Built Executive Team Eric Faulkner, MSc, MBA Lynne Kelley, MD, FACS Chief Technology Officer Chief Medical Officer Over 30 years of global biotechnology leadership Over 20 years of clinical and regulatory leadership across technical operations, CMC, product launch experience, guiding late-st
Slide 7: Outcome of Comprehensive Strategic Review
Outcome of Comprehensive Strategic Review Independent Analysis Across Clinical, Commercial and Capital Dimensions Underscores Need for a Disciplined Reset Legacy Pipeline Review Outcome of Review Defines Strategic Path Forward Strong scientific merit, but GBM focus not aligned with long-term growth
Slide 8: Focusing on Neurology and Oncology
Focusing on Neurology and Oncology Targeting Therapeutic Areas with Proven Investor Interest and Commercial Success, Capitalizing on the Experience of our New Executive Team Neurology Oncology Large, growing markets with Largest and most active significant unmet medical need sector in biotechnology
Slide 9: Neurology and Oncology Make Up Almost 50% of Investment and Deal Flow
Neurology and Oncology Make Up Almost 50% of Investment and Deal Flow Deal Flow 2022-2026 Neurology Oncology 18% 28% Deal Volume 205 457 Discovery: $430M Discovery: $1.1B 5% 2025 VC Raises by Preclinical: $665B Preclinical: $2B 5% Therapeutic ~Total Deal Area Value by Phase 1: $461B Phase 1: $1.8B 6
Slide 10: Diligence Process Guiding Search
Defined Target Asset Profile and Diligence Process Guiding Search Global Opportunity Search Target Asset Profile • Clear biological rationale and molecular basis for efficacy Market Assessment • Novel, and differentiated molecules Differentiation Analysis • Plausible rationale for clinical benefit •
Slide 11: Why CNSP, Why Now.
Why CNSP, Why Now. Unique Opportunity to Participate in a Public Biotech Strategic Pivot New Executive Team with Proven Execution Strategic Pivot Underway Purpose-built executive team with deep expertise Comprehensive review defining a disciplined path across neurology, oncology and rare disease for
Slide 12: cnspharma.com NASDAQ: CNSP
cnspharma.com NASDAQ: CNSP Investor Relations: JTC Team cnsp@jtcir.com
CNS Pharmaceuticals — Investor Presentation (March 2026) on 6ix